Analysen von Richard Vosser
| 21.04.20 | Sartorius vz. overweight | JP Morgan Chase & Co. | |
| 17.04.20 | Roche overweight | JP Morgan Chase & Co. | |
| 17.04.20 | Bayer Neutral | JP Morgan Chase & Co. | |
| 16.04.20 | Roche overweight | JP Morgan Chase & Co. | |
| 14.04.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 09.04.20 | Sanofi overweight | JP Morgan Chase & Co. | |
| 07.04.20 | Novartis Underweight | JP Morgan Chase & Co. | |
| 01.04.20 | Roche overweight | JP Morgan Chase & Co. | |
|
Werbung
|
|||
| 30.03.20 | Roche overweight | JP Morgan Chase & Co. | |
| 30.03.20 | Bayer Neutral | JP Morgan Chase & Co. | |
| 24.03.20 | Novartis Underweight | JP Morgan Chase & Co. | |
| 17.03.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 09.03.20 | Roche overweight | JP Morgan Chase & Co. | |
| 09.03.20 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 05.03.20 | Merck Neutral | JP Morgan Chase & Co. | |
| 02.03.20 | Bayer Neutral | JP Morgan Chase & Co. | |
| 27.02.20 | Bayer Neutral | JP Morgan Chase & Co. | |
| 25.02.20 | Sanofi overweight | JP Morgan Chase & Co. | |
| 18.02.20 | Bayer Neutral | JP Morgan Chase & Co. | |
| 11.02.20 | Sanofi overweight | JP Morgan Chase & Co. | |
| 06.02.20 | Roche overweight | JP Morgan Chase & Co. | |
| 06.02.20 | Sanofi overweight | JP Morgan Chase & Co. | |
| 06.02.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 05.02.20 | Merck Neutral | JP Morgan Chase & Co. | |
| 03.02.20 | Roche overweight | JP Morgan Chase & Co. | |
| 30.01.20 | Roche overweight | JP Morgan Chase & Co. | |
| 29.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 29.01.20 | Novartis Underweight | JP Morgan Chase & Co. | |
| 27.01.20 | Novartis Underweight | JP Morgan Chase & Co. | |
| 27.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 27.01.20 | Sanofi overweight | JP Morgan Chase & Co. | |
| 23.01.20 | Roche overweight | JP Morgan Chase & Co. | |
| 20.01.20 | Novartis Underweight | JP Morgan Chase & Co. | |
| 20.01.20 | Bayer Neutral | JP Morgan Chase & Co. | |
| 16.01.20 | Novartis Underweight | JP Morgan Chase & Co. | |
| 07.01.20 | Roche overweight | JP Morgan Chase & Co. | |
| 06.01.20 | Merck Neutral | JP Morgan Chase & Co. | |
| 06.01.20 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 06.01.20 | Sartorius vz. overweight | JP Morgan Chase & Co. | |
| 06.01.20 | Merck Neutral | JP Morgan Chase & Co. | |
| 06.01.20 | Novartis Underweight | JP Morgan Chase & Co. | |
| 06.01.20 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 06.01.20 | Sanofi overweight | JP Morgan Chase & Co. | |
| 06.01.20 | Bayer Neutral | JP Morgan Chase & Co. | |
| 06.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.01.20 | Roche overweight | JP Morgan Chase & Co. | |
| 06.01.20 | GSK Neutral | JP Morgan Chase & Co. | |
| 02.01.20 | Roche overweight | JP Morgan Chase & Co. | |
| 16.12.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 10.12.19 | Sanofi Neutral | JP Morgan Chase & Co. | |